Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (yeni pencere açar)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Kaynak‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

İndeks‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (yeni pencere açar)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (yeni pencere açar)

Banan M.

Kaynak‎: Ann Hematol 2013;92(3):289-99.

İndeks‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (yeni pencere açar)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (yeni pencere açar)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Kaynak‎: Transfusion 2007;47(10):1830-6.

İndeks‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (yeni pencere açar)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (yeni pencere açar)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Kaynak‎: Blood 1996;87(3):887-92.

İndeks‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (yeni pencere açar)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (yeni pencere açar)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Kaynak‎: Iran J Blood Cancer 2009;1(4):147-50.

İndeks‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (yeni pencere açar)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (yeni pencere açar)

Karimi M, Cohan N, Pishdad P.

Kaynak‎: Hematology 2015;20(1):53-7.

İndeks‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (yeni pencere açar)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (yeni pencere açar)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Kaynak‎: Int J Hematol 2012;95(1):51-6.

İndeks‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (yeni pencere açar)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (yeni pencere açar)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Kaynak‎: Hemoglobin 2014;38(2):115-8.

İndeks‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (yeni pencere açar)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (yeni pencere açar)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Kaynak‎: Blood 2013;121(12):2199-212.

İndeks‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (yeni pencere açar)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (yeni pencere açar)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Kaynak‎: Sci Rep. 2022;12(1):2752.

İndeks‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (yeni pencere açar)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (yeni pencere açar)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Kaynak‎: Haematologica 2004;89(10):1172-8.

İndeks‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (yeni pencere açar)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (yeni pencere açar)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Kaynak‎: Arch Iran Med 2009;12(3):295-7.

İndeks‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (yeni pencere açar)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (yeni pencere açar)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Kaynak‎: Eur J Haematol 1996;56(5):326-8.

İndeks‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (yeni pencere açar)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (yeni pencere açar)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Kaynak‎: J Matern Fetal Med 1999;8(1):1-7.

İndeks‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (yeni pencere açar)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (yeni pencere açar)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Kaynak‎: Acta Haematol 2004;111(4):189-95.

İndeks‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (yeni pencere açar)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (yeni pencere açar)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Kaynak‎: Ann Hematol 2001;80(8):492-5.

İndeks‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (yeni pencere açar)

Fetal globin induction--can it cure beta thalassemia? (yeni pencere açar)

Perrine SP.

Kaynak‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

İndeks‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (yeni pencere açar)